Antigenics Inc. (NASDAQ: AGEN) today announced that it has entered into definitive agreements to sell in a private placement 7 million shares of its common stock at a price of $3.00 per share, resulting in gross proceeds to the company of $21 million, before deducting placement agent fees and other offering expenses. The investors in this private placement will also receive five-year warrants to purchase up to 7 million additional shares of common stock at an exercise price of $3.75 per share.

Advanced Cell Technology, Inc. (OTCBB:ACTC – News) announced today that it completed a private placement with institutional and other accredited investors resulting in gross proceeds of $10 million.

The following statement has been issue by TTM Resources Inc. on April 24th.